TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How do MRD negativity rates with Dara-KRd compare to other treatment options in patients with NDMM?

Dec 12, 2019


The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, US, answers the question: How do minimal residual disease negativity rates with daratumumab, carfilzomib, lenalidomide and dexamethasone combination compare to other treatment options in patients with newly diagnosed multiple myeloma?

Based on the results from a single-arm phase II study, eight cycles of weekly daratumumab, carfilzomib, lenalidomide and dexamethasone resulted in 80% MRD negativity that is a much better rate compared with carfilzomib, lenalidomide and dexamethasone alone (40-50% MRD negativity).

How do MRD negativity rates with Dara-KRd compare to other treatment options in patients with NDMM?